Pharmaceuticals News & Press Release Distribution

Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's Phase III Study for Mild to Moderate COVID-19

SUZHOU, China, May 19, 2021 /PRNewswire/ -- On May 18, Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's ph...

2021-05-20 09:47 9534

Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021)

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced, data from three clinical studies of the PD-L1/CTLA-4 bispecific antibody KN046 will be presented in Poster session at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021) to be held...

2021-05-20 09:34 9219

ASCO 2021 | Ascentage Pharma to Announce Updated Data of Lisaftoclax (APG-2575) Demonstrating an ORR of Around 80% and Therapeutic Potential in Patients with R/R CLL/SLL in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that an abstract reporting on...

2021-05-20 08:44 5621

ASCO 2021 | Ascentage Pharma to Announce Updated Results Demonstrating Clinical Potential of Alrizomadlin (APG-115) Plus Pembrolizumab in Patients with Advanced Solid Tumors that Had Failed Immunotherapies in Oral Presentation

SUZHOU, China and ROCKVILLE, Md., May 20, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that abstracts reporting on t...

2021-05-20 08:17 5915

Transcenta Announced the Results of the Phase I Clinical Study of PD-L1 Antibody MSB2311 with Advanced Solid Tumors and Hematological Malignancies

SUZHOU, China, May 20, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) d...

2021-05-20 08:00 2924

I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021

* Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages * Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has...

2021-05-20 06:00 8733

Gracell Biotechnologies to Present Updated Results of GC012F FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma at ASCO 2021 and EHA 2021

SUZHOU, China and PALO ALTO, Calif., May 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, is presenting updated ...

2021-05-20 05:15 9053

Eurofins Discovery Launches Human Immune Models for COVID-19 New Therapeutic Discovery or Repurposing

ST. CHARLES, Mo., May 18, 2021 /PRNewswire/ -- Eurofins Discovery, the market leader in pharmacology services and drug discovery products with over forty years providing solutions for the pharmaceutical and biotech industry, announces the launch of new services in support of clients working to ad...

2021-05-18 21:00 2143

Atonarp Announces $50M Series D Financing to Scale its Molecular Sensing and Digital Diagnostics Testing Platforms

Michael Marks, Founding Partner for WRVI Capital, Joins the Atonarp Board and Former Berkeley Lights CFO Shaun Holt Joins as Atonarp's Chief Operating Officer TOKYO, May 18, 2021 /PRNewswire/ -- Atonarp, a leading manufacturer of molecular sensing and diagnostics products for the healthcare, phar...

2021-05-18 18:00 3531

Nanoform's final clinical results confirm value proposition to the pharma industry

HELSINKI, Finland, May 18, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform "), an innovative nanoparticle medicine enabling company, today announced the completion and final results of its clinical study. The primary, secondary and optional exploratory objectives of the study were all met. Th...

2021-05-18 13:48 1522

U.S. FDA Accepts Regulatory Submission for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, May 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX: 01801) and Eli Lilly and Company (NYSE: LLY) today jointly announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in...

2021-05-18 12:14 13377

Clover Announces Positive Preclinical Data for Second-Generation Protein-Based COVID-19 Vaccine Candidate Demonstrating Broad Neutralization Against Variants of Concern

* The publication is available as a pre-print on bioRxiv * Preclinical data demonstrates that a modified B.1.351 S-Trimer vaccine candidate induces broad neutralization against both the original SARS-CoV-2 strain and variants of concern (VoC) including the South African variant * A single bo...

2021-05-18 11:50 3334

Farrer Park Hospital Elevates Cancer Care with PIPAC Treatment for Late to End-stage Cancer Patients

SINGAPORE, May 18, 2021 /PRNewswire/ -- Farrer Park Hospital has introduced the pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment for patients with peritoneal cancer, off...

2021-05-18 08:15 2367

EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines

PROVIDENCE, R.I., May 17, 2021 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") announces the publication"Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation" in NPJ Vaccines. This research identifies peptide epitopes associated with T...

2021-05-17 20:54 2627

INOVIO Announces Appointment Of Roger Dansey, M.D., to its Board of Directors

Dr. Dansey, Seagen's Chief Medical Officer, brings extensive expertise in immuno-oncology and drug development Appointment of industry leader in drug development expands the Board's diverse industry, clinical development, research and commercialization expertise PLYMOUTH MEETING, Pa., May 17, 20...

2021-05-17 20:00 4853

Everest Medicines Announces China NMPA Has Accepted Biologics License Application for Sacituzumab Govitecan-Hziy in Metastatic Triple-Negative Breast Cancer

SHANGHAI, May 17, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inGreater China and other parts of Asia, announced today that the C...

2021-05-17 16:51 4315

Nippon Express (China) Becomes First Japanese Company to Acquire GDP Certification in China

TOKYO, May 17, 2021 /PRNewswire/ -- Nippon Express (China) Co., Ltd. (hereinafter "NE China"), a local subsidiary of Nippon Express Co., Ltd., has obtained Good Distribution Practice (GDP) certification, effectiveMonday, March 29, 2021, for its Shanghai Pudong Airport CFS, making it the first Jap...

2021-05-17 15:00 4530

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...

2021-05-17 09:00 5164

Antengene Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial

SHANGHAI and HONG KONG, May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onc...

2021-05-17 08:00 3577

Luye Life Sciences Unveils Cutting-edge Advances in Gene and Cell Therapy at ASGCT 2021

BOSTON, May 13, 2021 /PRNewswire/ -- The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company's latest preclinical developments in ...

2021-05-14 11:58 2712